Wed, Oct 23, 2019 · 9:00

Across 3 packed days, join Europe’s NASH stakeholders as they lead directive discussions, share actionable insights and analyse the next 12 months of NASH drug development through a tighter lens.

- Address pharma-physician disconnect in Europe with the EMA
- Understand considerations from European Health Technology Assessment Bodies when assessing the value of medicines for NASH with NICE
- Review regulatory guidance for NASH with compensated cirrhosis with the FDA

Join 80+ other NASH drug developers to navigate solutions for these and 10+ other rate limiting factors as the first NASH therapies receive approval.


Pharma and Biotech Drug Developer/Gold: Conference + Workshop Day: GBP 2498.0,
Pharma and Biotech Drug Developer/Silver: Conference Only: GBP 1699.0,
Pharma and Biotech Drug Developer/Bronze: Workshop Day Only: GBP 899.0,
Standard/Gold: Conference + Workshop Day: GBP 3398.0,
Standard/Silver: Conference Only: GBP 2599.0,
Standard/Bronze: Workshop Day Only: GBP 1199.0,
Academic/Gold: Conference + Workshop Day: GBP 1698.0,
Academic/Silver: Conference Only: GBP 1199.0,
Academic/Bronze: Workshop Day Only: GBP 599.0

Speakers: Frank Anania, Division of Gastroenterology and Inborn Errors Products, FDA, Massimo Pinzani, Professor of Medicine, UCL, Vincenzo Costigliola, Founder and President, European Medical Association (EMA), Achim Kautz, Founder, Leberhilfe Projekt, Bevin Gangadharan, Research Associate, University of Oxford, Christine Reynet, Director, McC+R&D Consulting, Daren Ure, Director of Research and Development, ContraVir Pharmaceuticals, David Blakey, Chief Scientific Officer, MiNA Therapeutics, Elias Papatheodorou, Chief Executive Officer, Genkyotex, Felix Yeh, Scientist, Genentech, Giampiero “GP” Carlo, Head of Brand: Cotadutide, Cardiovascular, Renal and Metabolism (CVRM), AstraZeneca, Ian Rowe, University Academic Fellow and Hepatologist, University of Leeds, Jacobo Miranda, Postdoctoral Researcher Collaborator, LiSyM, Jeanette Kusel, Director Scientific Advice, National Institute for Health and Care Excellence (NICE), Jelena Mann, Professor of Epigenetics, Fibrosis Research Group Newcastle University, Kari Wong, Senior Study Director, Metabolon, Livia Alimenia, European Office Director, Global Liver Institute, Marc Hertz, Chief Executive Officer, GRI Bio, Marian McNeil, Chief Operating Officer, Stratified Medicine Scotland Innovation Centre, Michel de Baar, Executive Director – Business Development, Licensing, Infectious Diseases, Vaccines, Cardiovascular and Metabolic Diseases, MSD, Naim Alkhouri, Director of the Metabolic Health Centre, Texas Liver Institute, Nicolas Guisot, Research Fellow, RedX Pharma, Nikolai Naoumov, Executive Director, Hepatology Sciences and Innovation, Novartis, Olga Vvedenskaya, Postdoctoral Researcher Member, LiSyM, Peter Traber, Partner, Alacrita Consulting, Richard Torstenson, Director International Clinical Development NASH, Allergan, Tariq Sethi, Co-founder, Galecto Biotech, Thomas Baumert, Professor of Medicine, Institute of Viral and Liver Disease, Inserm, Trent Ross, Principal Scientist, Metabolism, Pfizer, John O’Neil, Chief Scientific Officer, XYLYX

Venue Details: The Waldorf Hilton, London